Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Free Report) saw unusually large options trading activity on Wednesday. Traders bought 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the average volume of 53 put options.

Institutional Trading of Maravai LifeSciences

Institutional investors have recently modified their holdings of the company. Zions Bancorporation N.A. bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at about $28,000. Gladius Capital Management LP purchased a new position in shares of Maravai LifeSciences in the 4th quarter valued at approximately $30,000. Meeder Asset Management Inc. purchased a new position in shares of Maravai LifeSciences in the 1st quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. raised its position in shares of Maravai LifeSciences by 96.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after purchasing an additional 1,662 shares during the last quarter. Finally, Signaturefd LLC raised its position in shares of Maravai LifeSciences by 99.9% in the 3rd quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock valued at $34,000 after purchasing an additional 1,681 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Stock Up 1.2 %

Shares of Maravai LifeSciences stock opened at $8.61 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 8.00 and a quick ratio of 7.41. Maravai LifeSciences has a 1 year low of $4.52 and a 1 year high of $16.62. The firm’s 50-day moving average is $6.98 and its two-hundred day moving average is $6.87. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -9.57 and a beta of 0.01.

Maravai LifeSciences (NASDAQ:MRVIGet Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. The firm had revenue of $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. As a group, research analysts expect that Maravai LifeSciences will post -0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Royal Bank of Canada raised their price target on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Stifel Nicolaus reduced their price target on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, February 23rd. Finally, Bank of America raised shares of Maravai LifeSciences from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $10.00 to $8.00 in a research note on Tuesday, December 12th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.13.

Get Our Latest Research Report on Maravai LifeSciences

Maravai LifeSciences Company Profile

(Get Free Report)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Read More

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.